Article Sidebar
Published:
Jul 12, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Bioinformatics and experimental validation of mechanisms underlying lenvatinib therapy for hepatocellular carcinoma
Abstract
Purpose: To investigate and validate the therapeutic targets of lenvatinib in hepatocellular carcinoma (HCC), using bioinformatics and in vitro experiments.
Methods: The potential core targets of lenvatinib were identified through screening and analysis of various databases. The core targets were validated using in vitro experiments.
Results: The results showed that lenvatinib significantly affected pro-survival signals of MAPK signaling pathway which activate and regulate a range of cellular activities. Molecular docking revealed that key proteins may be the key targets of lenvatinib in its systematic anti-tumor effect on HCC. Results from quantitative reverse transcription-polymerase chain reaction (qRT-PCR) revealed that lenvatinib regulated the expressions of key genes associated with HCC.
Conclusion: The findings of this investigation provide a new insight for further development of lenvatinib as a drug for HCC treatment.
